Stocktoria
ANI PHARMACEUTICALS INC ANIP
ANI PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M | $208.5M | $206.5M | $201.6M | $176.8M | $128.6M |
| R&D expense | $51.7M | $44.6M | $34.3M | $22.3M | $11.4M | $16.0M | $19.8M | $15.4M | $9.1M | $2.9M |
| SG&A expense | $317.7M | $249.6M | $161.7M | $124.0M | $84.3M | $65.0M | $55.8M | $44.1M | $31.6M | $27.8M |
| Operating income | $111.1M | $584,000 | $47.0M | -$35.3M | -$39.8M | -$16.0M | $16.4M | $35.4M | $28.3M | $20.1M |
| Income tax | $17.5M | -$3.7M | $1.1M | -$14.8M | -$13.5M | -$3.4M | -$2.9M | $4.6M | $17.4M | $4.7M |
| Net income | $78.3M | -$18.5M | $18.8M | -$47.9M | -$42.6M | -$22.5M | $6.1M | $15.5M | -$1.1M | $3.9M |
| EPS (diluted) | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 | $-1.88 | $0.50 | $1.30 | $-0.09 | $0.34 |
| Operating cash flow | $185.2M | $64.0M | $119.0M | -$31.2M | $3.3M | $15.3M | $45.6M | $67.1M | $39.4M | $27.5M |
| Free cash flow | $171.4M | $47.8M | $110.1M | -$40.1M | $765,000 | $9.1M | $39.0M | $61.3M | $29.1M | $22.9M |
| Cash & equivalents | $285.6M | $144.9M | $221.1M | $48.2M | $100.3M | $7.9M | $62.3M | $43.0M | $31.1M | $27.4M |
| Inventory | $143.1M | $136.8M | $111.2M | $105.4M | $81.7M | $60.8M | $48.2M | $40.5M | $37.7M | $26.2M |
| Total assets | $1.4B | $1.3B | $904.4M | $760.1M | $771.6M | $461.2M | $456.8M | $430.6M | $412.1M | $322.9M |
| Total liabilities | $899.7M | $855.9M | $446.8M | $421.5M | $412.9M | $265.5M | $244.0M | $233.3M | $237.4M | $153.2M |
| Shareholders' equity | $540.7M | $403.7M | $432.7M | $313.7M | $333.9M | $195.7M | $212.8M | $197.3M | $174.8M | $169.6M |
Growth · year-over-year · Revenue CAGR 23.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +43.8% | +26.2% | +53.9% | +46.4% | +3.7% | +0.9% | +2.5% | +14.0% | +37.5% | +68.5% |
| Net income growth | — | -198.6% | — | — | — | -470.0% | -60.7% | — | -127.4% | -74.4% |
| EPS growth | — | -222.4% | — | — | — | -476.0% | -61.5% | — | -126.5% | -74.2% |
| Free cash flow growth | +258.7% | -56.6% | — | -5339.1% | -91.6% | -76.6% | -36.4% | +111.1% | +26.8% | +51.9% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.